Drug Profile
Dalazatide
Alternative Names: Debio-0824; ShK-186Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Airmid; University of California at Irvine
- Developer Kineta; KPI Therapeutics; Seattle Childrens Research Institute; University of California at Irvine; University of Groningen
- Class Amides; Peptides; Proteins
- Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inclusion body myositis; Inflammatory bowel diseases; Lupus nephritis; Multiple sclerosis; Obesity; Plaque psoriasis; Psoriatic arthritis; Vasculitis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Inclusion body myositis in USA (SC, Injection)
- 28 Jul 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (SC, Injection)
- 28 Jul 2019 No recent reports of development identified for research development in Multiple-sclerosis in USA (SC, Injection)